New hope for tough lung cancer: expanded access to targeted drug
NCT ID NCT07535359
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other suitable options and cannot join a clinical trial. The goal is to offer a potential treatment option while gathering more information about the drug's effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Cancer Institute
AVAILABLEDurham, North Carolina, 27710, United States
-
Health Partners Oncology
AVAILABLESaint Paul, Minnesota, 55101, United States
-
University of Texas Southwestern Medical
AVAILABLEDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer
- Experimental cancer therapy targets tough tumors with radioactive precision